Matthew Gubens
Matthew Gubens, MD, MS, FASCO is Professor of Medicine at UCSF, where he practices as a thoracic medical oncologist and serves as Medical Director of Thoracic Medical Oncology. He is also Chair of the UCSF Cancer Center-wide Protocol Review and Monitoring Committee overseeing scientific review of all cancer research at UCSF. Dr. Gubens is the current Chair of the ASCO Evidence Based Medicine Committee which oversees the ASCO Guidelines program, and he also co-chairs the ASCO Thoracic Guideline Advisory Group. Dr. Gubens serves on the National Comprehensive Cancer Network panels for non-small cell lung cancer, mesothelioma, and thymic malignancies. Dr Gubens completed his BA at Yale, his MS at the Harvard School of Public Health, and his MD at Stanford, and trained in internal medicine residency at UCSF and then medical oncology at Stanford.
Financial relationships
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:AstraZenecaTopic:ad board/consultingDate added:01/12/2023Date updated:04/19/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:BMSTopic:ad board/consultingDate added:01/12/2023Date updated:04/19/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Cardinal HealthTopic:ad board/consultingDate added:01/12/2023Date updated:04/19/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Genentech/RocheTopic:ad board/consultingDate added:01/12/2023Date updated:04/19/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:GemzymeTopic:ad board/consultingDate added:01/12/2023Date updated:04/19/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:GuardantTopic:ad board/consultingDate added:01/12/2023Date updated:04/19/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:iTeosTopic:ad board/consultingDate added:01/12/2023Date updated:04/19/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:SanofiTopic:ad board/consultingDate added:01/12/2023Date updated:04/19/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:SurfaceTopic:ad board/consultingDate added:01/12/2023Date updated:04/19/2024